Abcam’s (ABC) “Buy” Rating Reaffirmed at Berenberg Bank
A number of other brokerages also recently commented on ABC. Peel Hunt reissued a hold rating and issued a GBX 750 ($10.03) price objective on shares of Abcam in a research report on Monday, September 11th. Panmure Gordon reissued a sell rating on shares of Abcam in a research report on Monday, September 11th. Numis Securities increased their price objective on shares of Abcam from GBX 1,116 ($14.92) to GBX 1,200 ($16.04) and gave the company an add rating in a research report on Tuesday, September 12th. Finally, JPMorgan Chase & Co. reissued a neutral rating and issued a GBX 864 ($11.55) price objective on shares of Abcam in a research report on Tuesday, September 12th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. Abcam has a consensus rating of Hold and an average price target of GBX 996 ($13.32).
Shares of Abcam (LON:ABC) opened at GBX 1,089 ($14.56) on Friday. Abcam has a 52 week low of GBX 9.73 ($0.13) and a 52 week high of GBX 1,113 ($14.88). The firm has a market cap of $2,230.00 and a P/E ratio of 5,185.71.
Abcam Company Profile
Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company’s purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways.
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with Analyst Ratings Network's FREE daily email newsletter.